Quoin Pharmaceuticals Ltd DRC - Asset Resilience Ratio
Quoin Pharmaceuticals Ltd DRC (QNRX) has an Asset Resilience Ratio of 55.76% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Quoin Pharmaceuticals Ltd DRC (QNRX) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Quoin Pharmaceuticals Ltd DRC's Asset Resilience Ratio has changed over time. See Quoin Pharmaceuticals Ltd DRC shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Quoin Pharmaceuticals Ltd DRC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see QNRX market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.58 Million | 55.76% |
| Total Liquid Assets | $3.58 Million | 55.76% |
Asset Resilience Insights
- Very High Liquidity: Quoin Pharmaceuticals Ltd DRC maintains exceptional liquid asset reserves at 55.76% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Quoin Pharmaceuticals Ltd DRC Industry Peers by Asset Resilience Ratio
Compare Quoin Pharmaceuticals Ltd DRC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Quoin Pharmaceuticals Ltd DRC (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Quoin Pharmaceuticals Ltd DRC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 66.42% | $10.43 Million | $15.71 Million | -1.74pp |
| 2023-12-31 | 68.15% | $8.29 Million | $12.17 Million | -0.96pp |
| 2022-12-31 | 69.12% | $9.99 Million | $14.46 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $9.36 Million | -- |
| 2017-12-31 | 46.09% | $4.03 Million | $8.75 Million | -26.62pp |
| 2016-12-31 | 72.71% | $6.41 Million | $8.81 Million | +14.12pp |
| 2015-12-31 | 58.60% | $2.01 Million | $3.43 Million | -- |
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Net… Read more